Author Correction: Casdatifan durable response linked to HIF-2α in kidney cancer

The authors of a kidney cancer study issued a correction to their paper on casdatifan, a drug targeting HIF-2α. The correction addresses the reported connection between durable clinical response and HIF-2α biology. This clarifies the original findings for researchers and clinicians following the treatment's development.

Sources (1)